Press Release Details

View all news

Limbach Laboratory Network Group Selects Bruker´s MALDI Biotyper for Mass Spectrometry-Based Microbial Identification by Molecular Fingerprinting

September 15, 2009

BREMEN, Germany--(BUSINESS WIRE)--Sep. 15, 2009-- Prior to the 61st Annual Meeting of the German Society for Hygiene and Microbiology on September 20-23, 2009 in Goettingen, Bruker Daltonics announces a new framework agreement with the Limbach laboratory network, concerning microbial identification based on MALDI-TOF mass spectrometry. According to the agreement, Bruker Daltonics will be the exclusive provider of MALDI-TOF based microbial identification solutions for the Limbach network of more than 30 European clinical laboratories.

Since being introduced at the Labor Limbach headquarters in Heidelberg in 2007, the MALDI Biotyper has been established in a number of other laboratories in the Limbach association. The MALDI Biotyper is currently in use in Limbach clinical microbiology centers in Germany in Heidelberg, Koblenz, Hamburg, Karlsruhe, Singen, Magdeburg and Nordhorn. After the signing of the new framework agreement, Bruker has received additional orders for MALDI Biotyper systems from the Limbach laboratories in Ravensburg and in Freiburg, and an additional system was ordered for Limbach site in Heidelberg. The Limbach laboratory network intends to introduce this new molecular technology broadly as a very fast routine method for microbial identification in additional Limbach laboratories in Germany. Moreover, Bruker and Labor Limbach intend to jointly introduce the MALDI Biotyper in Poland via Limbach´s laboratories in Warsaw and Gdansk.

Dr. Anne-Marie Fahr, Head of Microbiology at Labor Limbach, commented: “In contrast to previous introductions of other technologies, in the case of the MALDI Biotyper we have seen a very wide acceptance of this new approach nearly throughout our entire network. Bruker is the leading supplier of MALDI-TOF mass spectrometry with a global support and service network, and is thus the reliable long-term partner that we were looking for in the Limbach association.”

Dr. Wolfgang Pusch, Vice President for Clinical Research Solutions & IVD at Bruker Daltonics, added: “This exclusive framework agreement is a major step ahead into a new era of fast molecular identification in clinical microbiology. The last two years have shown the fundamental advantages of our MALDI Biotyper approach for microbial identification, i.e. higher specificity, faster time-to-result and lower consumables costs. Moreover, the MALDI Biotyper has proven to be robust and easy to use in demanding environments. We are very pleased that our MALDI Biotyper fulfils the high expectations of leading clinical laboratories like the Labor Limbach association, and we look forward to presenting the IVD-CE marked MALDI Biotyper at the upcoming 61st DGHM Annual Meeting.”

About the Bruker MALDI Biotyper

Bruker’s dedicated MALDI Biotyper solution enables molecular identification, taxonomical classification or dereplication of microorganisms like bacteria, yeasts and fungi. Classification and identification of microorganisms is achieved reliably and quickly using proteomic fingerprinting by high-throughput MALDI-TOF mass spectrometry. Applications include clinical routine microbial identification, environmental and pharmaceutical analysis, taxonomical research, food and consumer product processing and quality control, as well as marine microbiology. Bruker’s robust MALDI Biotyper method requires minimal sample preparation efforts and offers low consumables cost per sample. The MALDI Biotyper is available in a research-use-only version, as well as in an IVD-CE version according to EU directive EC/98/79 in certain European countries. For more information, please visit


For more information about Bruker Daltonics and Bruker Corporation (NASDAQ: BRKR), please visit and


Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to adverse changes in conditions in the global economy and volatility in the capital markets, the integration of businesses we have acquired or may acquire in the future, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing, competition, dependence on collaborative partners and key suppliers, capital spending and government funding policies, changes in governmental regulations, intellectual property rights, litigation, and exposure to foreign currency fluctuations. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2008, our most recent quarterly reports on Form 10-Q and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements other than as required by law.

Photos/Multimedia Gallery Available:

Source: Bruker Daltonics

MALDI Biotyper Marketing, Bruker Daltonics
Karin Hoffmann, +49-421-2205-2041

Categories: Press Releases
View all news